Reduced moxifloxacin exposure in patients with tuberculosis and diabetes

Eur Respir J. 2019 Sep 5;54(3):1900373. doi: 10.1183/13993003.00373-2019. Print 2019 Sep.

Bart G J Dekkers¹, Mathieu S Bolhuis², Lies Ter Beek^{3

4

5}, Wiel C M de Lange^{3

4}, Tjip S van der Werf^{3

6}, Jan-Willem C Alffenaar^{2

7}, Onno W Akkerman^{3

4}

¹ University of Groningen, University Medical Center Groningen, Dept of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands b.g.j.dekkers@umcg.nl.
² University of Groningen, University Medical Center Groningen, Dept of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands.
³ University of Groningen, University Medical Center Groningen, Dept of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands.
⁴ University of Groningen, University Medical Center Groningen, Tuberculosis Center Beatrixoord, Haren, The Netherlands.
⁵ Hanze University of Applied Sciences, Nutrition and Dietetics, Groningen, The Netherlands.
⁶ University of Groningen, University Medical Center Groningen, Dept of Internal Medicine, Groningen, The Netherlands.
⁷ Sydney School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.

No abstract available

Publication types